Many Amer­i­cans have flocked to cheap­er, com­pound­ed ver­sions of GLP-1 weight loss drugs in lieu of brand-name treat­ments. That com­pe­ti­tion is cut­ting in­to de­mand for No­vo Nordisk’s pre­scrip­tions, a com­pa­ny ex­ec said Wednes­day.

“Our lat­est mar­ket in­tel­li­gence does tell us and show us that it is hav­ing an im­pact and it is grow­ing faster than we had an­tic­i­pat­ed,” David Moore, No­vo’s head of US op­er­a­tions, said dur­ing the drug­mak­er’s fourth-quar­ter earn­ings call.

He was re­spond­ing to a ques­tion about com­pound­ed drugs’ ef­fects on de­mand for the com­pa­ny’s prod­ucts. Com­pound­ed drugs are copies of brand-name treat­ments mixed up by phar­ma­cies, and they’re typ­i­cal­ly per­mit­ted on­ly when there’s a drug short­age.

The fight over who gets con­trol of Re­vance Ther­a­peu­tics and its Botox com­peti­tor, Daxxi­fy, is com­ing to a close.

On Wednes­day, Re­vance said it’s mov­ing for­ward with its sale to Crown Lab­o­ra­to­ries. The two com­pa­nies had been in talks for months when, in Jan­u­ary, Re­vance’s com­mer­cial part­ner Teox­ane sub­mit­ted a com­pet­ing bid.

Crown had ini­tial­ly of­fered $6.66 per share in Au­gust to ac­quire Re­vance. Short­ly af­ter, Teox­ane ini­ti­at­ed a con­tract dis­pute with Re­vance that de­layed the deal and was a fac­tor in Crown’s de­ci­sion to slash its of­fer to $3.10 a share. Teox­ane, which de­vel­ops der­mal fillers, then pro­posed to buy Re­vance for $3.60 per share.

All nine late-stage kid­ney can­cer pa­tients in a Phase 1 tri­al of a per­son­al­ized vac­cine re­mained can­cer-free af­ter about three years of re­ceiv­ing treat­ment, re­searchers wrote in a Na­ture pa­per pub­lished on Wednes­day.

Co-prin­ci­pal in­ves­ti­ga­tors Toni Choueiri from Dana-Far­ber and David Braun from Yale said they treat­ed the nine pa­tients, with stage III or IV clear cell re­nal cell car­ci­no­ma, with a per­son­al­ized can­cer vac­cine af­ter surgery. Five pa­tients al­so re­ceived Bris­tol My­ers Squib­b's im­munother­a­py Yer­voy with the vac­cine.

Ac­cord­ing to Dana-Far­ber, the team us­es pre­dic­tive al­go­rithms to de­ter­mine which neoanti­gens to in­clude in each three-shot vac­cine se­ries based on their like­li­hood to in­duce an im­mune re­sponse.

“This ap­proach is tru­ly dis­tinct from vac­cine at­tempts in kid­ney can­cer," Braun said in a state­ment. "We be­lieve this work can form a foun­da­tion for the de­vel­op­ment of neoanti­gen vac­cines in kid­ney can­cer."

The race is on be­tween Ku­ra On­col­o­gy and Syn­dax Phar­ma­ceu­ti­cals.

On Wednes­day, Ku­ra and its part­ner Ky­owa Kirin an­nounced that their tar­get­ed treat­ment ziftomenib suc­ceed­ed in a key study for a sub­set of ad­vanced acute myeloid leukemia pa­tients and that Ku­ra will be sub­mit­ting an ap­pli­ca­tion to the FDA in the sec­ond quar­ter of the year.

Ziftomenib blocks a cell growth reg­u­la­tor called menin, and the tri­al looked at how many pa­tients had a com­plete re­sponse to the drug. Ku­ra pres­i­dent and CEO Troy Wil­son de­clined to pro­vide any da­ta on the suc­cess­ful Phase 2 re­sult, say­ing the biotech had sub­mit­ted the re­sults to a “large US med­ical con­fer­ence” tak­ing place next quar­ter.

Eye­Point Phar­ma­ceu­ti­cals, a biotech at­tempt­ing to grab a sliv­er of Re­gen­eron's share of the de­gen­er­a­tive eye dis­ease mar­ket, said six-month re­sults show its drug met the pri­ma­ry end­point in a Phase 2 tri­al.

At first, the da­ta did­n't ap­pear to please in­vestors. The read­out sent Eye­Point's shares EYPT down as much as 25% be­fore Wednes­day's open­ing bell. But the stock re­versed af­ter the mar­kets opened, with shares trend­ing up about 10%.

The study, dubbed VERONA, is test­ing Du­ravyu in pa­tients with di­a­bet­ic mac­u­lar ede­ma. The Boston-area biotech last fall raised $161 mil­lion on the back of ear­li­er in­ter­im da­ta from that tri­al.